Chartmaster
6日前
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery.
PTSD affects veterans, first responders, survivors of sexual assault and domestic violence, children exposed to trauma, families, and communities. According to the U.S. Department of Veterans Affairs' National Center for PTSD, approximately 5% of U.S. adults experience PTSD in any given year, representing about 13 million Americans in 2020. That number may not fully reflect those who remain undiagnosed, do not report symptoms, or lack access to care.
"PTSD is not simply a market category. It is the veteran who comes home but never fully returns to peace. It is the child who carries abuse into adulthood. It is the woman rebuilding her life after violence. It is human suffering that deserves serious science," said Mr. John Jones, CBIH Treasurer, Director, and former 101st Airborne Division sergeant. "This work was developed with care, purpose, and compassion as part of our mission to build meaningful scientific assets for responsible trauma-related research."
CBIH's PTSD-focused work centers on a key scientific connection: cannabinoids and psilocybin may address different but related dimensions of trauma biology. Cannabinoids may help support pathways associated with stress response, sleep, inflammation, emotional regulation, and the endocannabinoid system, while psilocybin has shown encouraging potential in controlled clinical research related to neuroplasticity, emotional processing, fear-related learning, cognitive flexibility, and mood.
"The Company is building more than a portfolio of patent-related concepts; it is building a broader scientific foundation for cannabinoid-based biotechnology at a time when the cannabis sector is about to turn a corner from traditional market perceptions toward a new era defined by science, regulation, intellectual property, and medical innovation," said Dante Picazo, CEO of CBIH.
The firm's intellectual property work is designed to support a cross-category regulated medical research platform beyond any single condition, product, or market category, allowing the Company to organize its scientific ideas around cannabinoids, psilocybin, formulation systems, therapeutic pathways, and future medical applications, CBIH seeks to define, protect, and advance the scientific logic behind next-generation therapeutic development.
As cannabinoid- and psychedelic-related medicine moves toward a more regulated and research-driven future, CBIH is assembling scientific assets designed to give the Company room to move, room to partner, and room to become the leading name within the emerging field of plant-derived therapeutic science.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: https://x.com/CBIHMD
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/301379_90956996e4cecb8d_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301379
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/301379/130
Chartmaster
2週前
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
NEWSFILE CORP 5:00 AM ET 6/8/2026
Symbol Last Price Change
CBIH 0.0004up 0 (0%)
QUOTES AS OF 12:00:00 AM ET 06/05/2026
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc.(CBIH) , a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchising opportunities, appropriate commercialization structures, product standards, quality control, and responsible market entry.
VitaCookies has been developed over nearly two years of structured research and formulation work by CBIH's multidisciplinary research and development team, including physicians, scientists, Ph.D. chemists, Ph.D. biologists, and pharmacists. "Proper nutrition is fundamental to the body's normal biological function, metabolic balance, immune support, and overall wellness. When nutrition is not properly addressed, the body cannot perform at its full functional capacity," said Rosangel Andrades, M.D., CBIH R&D Director. "Guided by this principle, the formulation process incorporated a nutrition-focused product design approach, evaluating ingredient function, nutrient profile, compatibility, safety profile, sensory performance, flavonoid and terpenoid relevance where appropriate, cannabinoid interactions, dosage strategy, flavor behavior, and consumer usability before advancing the product line."
The selected fruit profiles for each VitaCookies formulation were chosen based on the intended wellness category and the needs associated with specific medical conditions, helping support natural flavor, sensory quality, nutritional purpose, and consumer acceptance. Through this approach, CBIH believes it has developed a science-driven wellness platform that is both functional and consumer-friendly.
The therapeutic essence of VitaCookies is centered on transforming complex wellness needs into a simple daily product experience. The platform is being developed across multiple condition-focused wellness categories, including pain support, stress, anxiety, osteoporosis-related support, diabetes-related wellness, fibromyalgia support, digestive wellness, and PTSD-related support. CBIH also recognizes that menopause-related support and women's wellness have historically been underserved in traditional medicine, research, and product innovation, creating an opportunity to bring greater scientific and consumer-focused attention to these important needs.
Early internal product-development feedback has been highly encouraging. While initial formulations demonstrated strong functional potential, they also presented a medicinal taste profile, leading CBIH to align with cookie specialists with approximately 75 years of tradition and experience in cookie production. CBIH believes this collaboration has helped shape a fruit-forward product platform designed to combine cannabinoid-based formulation science with improved flavor, texture, and consumer acceptance.
The Company expects to provide additional updates as it advances through the licensing process, finalizes its manufacturing pathway, evaluates scalable franchising opportunities, and prepares VitaCookies for a disciplined and compliant market introduction. Through a responsible franchising strategy, CBIH seeks to support faster growth and broader access to a science-driven wellness platform designed to promote comfort, daily support, and quality of life for people often overlooked by traditional medicine, creating a pathway whereby VitaCookies may serve as a non-traditional form of wellness and medical support in a traditional world.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: https://x.com/CBIHMD
Instagram: www.instagram.com/CBIHSTOCK
Corporate Logo
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300420
SOURCE Cannabis Bioscience International Holdings(CBIH)
Chartmaster
3週前
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation.
The Company views this milestone as part of its broader strategy to build research-driven intellectual property in cannabinoid biotechnology. CBIH believes this progress comes at an important moment for cannabinoid medicine, as the DEA administrative hearing related to the proposed rescheduling of marijuana from Schedule I to Schedule III, anticipated to begin on June 29, 2026, may help create a more constructive environment for research, medical development, and institutional participation.
"CBIH is building its strategy around science, intellectual property, formulations, and regulatory discipline," said Dante Picazo, Chief Executive Officer of Cannabis Bioscience International Holdings, Inc. "While much of the cannabis sector has been driven by market cycles and short-term expectations, our firm is focused on creating a research-driven biotechnology platform in complex disease areas where inflammation, oxidative stress, immune response, mitochondrial function, and gene-expression regulation may overlap. We believe this approach can support future opportunities for licensing, clinical collaboration, manufacturing relationships, strategic partnerships, and long-term shareholder value."
Epigenetic regulation refers to biological mechanisms that may influence how cells respond to stress without changing the DNA sequence itself. In melanoma research, these mechanisms may be relevant to tumor behavior, immune response, disease progression, and aging-related cellular stress. "Our melanoma-related program reflects CBIH's interest in the relationship between the Endocannabinoid System, epigenetic regulation, and complex oncology-related disease mechanisms," said Jennifer Salguero, Biologist, PhD in Science, University of São Paulo, Brazil, and Chief Patent Officer of CBIH. "This work supports our broader commitment to disciplined cannabinoid research, patent development, and formulation science."
This initiative forms part of CBIH's portfolio of 25 finalized patent applications, including 10 applications already submitted to the USPTO and 15 additional applications finalized and ready for submission. The portfolio covers neurological, autoimmune, oncological, metabolic, and other complex disease areas, within a broader body of more than 100 medical formulation intellectual property assets.
As cannabinoid-based medicine continues to evolve, CBIH believes that scientific credibility, intellectual property protection, and responsible regulatory execution will be essential to building lasting value. The Company intends to continue advancing a sustainable competitive advantage from its position as a serious participant in the emerging cannabinoid biotechnology sector.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: https://x.com/CBIHMD
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/299514_6a55ddc6c4f98aca_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299514
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/299514/130
Chartmaster
5月前
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions.
CBIH clarifies that this communication reflects a serious corporate and executive planning approach intended to protect business value and accelerate operational execution. The Company believes that, without adequate working capital, scaled sales, and a sustained product launch into the market, the risks of competitive lag increase, the capacity to convert research into recurring revenue is constrained, and the organization becomes exposed to operational frictions that may affect continuity and growth.
If completed, the proceeds would be used primarily to enable and execute an integrated plan that includes, among other corporate purposes: (i) the commercial launch and expansion of CBIH's product portfolio—including VitaCookies, ointments, tinctures, and capsules; (ii) strategic costs associated with the protection, maintenance, and defense of the Company's intellectual property and patent portfolio; and (iii) the costs to establish, deploy, and scale CBIH's statewide educational programs, including the infrastructure and execution required for implementation.
In parallel, CBIH continues to execute an agenda of alliances and coordination with ecosystem participants including technical teams, healthcare organizations, and institutional counterparties with the objective of converting interest into verifiable work plans, strengthening operational capabilities, compliance, and quality standards oriented toward results.
"This evaluation is not about headlines; it is about execution discipline and the protection of corporate value," said Rebeka Lopez, CPA, Director of Finance at CBIH. "Our objective is to enable working capital to bring products to market in an orderly manner, sustain appropriate sales, and support the defense of our intellectual property assets and educational programs with a serious business-focused approach."
With respect to financing, CBIH stated that its approach is to structure any alternative with compliance standards and prudent communications. At this stage, the Company is reviewing scenarios, costs, and operational priorities, as well as the optimal sequencing for execution and disclosure, seeking consistency with its public reporting obligations.
CBIH emphasizes that, as of the date hereof, there is no certainty that an offering will be pursued, nor as to the final terms, timing, structure, or definitive amount, and any decision will be subject to additional internal evaluations, professional advice, and the applicable regulatory framework.
CBIH believes that this evaluation stage represents a reasonable and strategic opportunity to convert years of medical research, medicinal formulation development, and intellectual asset building into tangible and sustainable outcomes. For nearly two decades, the Company has invested work and capital in applied science, intellectual property, and education, including audiobooks, electronic books, and educational videos, with the purpose of elevating standards for the responsible, evidence-based use of cannabinoid-derived therapies.
In this context, CBIH views the current environment, driven by the federal rescheduling of cannabis, as an inflection point that enables the Company to execute a comprehensive commercial and educational plan with greater clarity, rigor, and reach. The Company intends to capitalize on this moment with discipline and determination by accelerating the launch of its portfolio and consolidating its strategic programs, with the expectation that this step will contribute to realizing, finally, the value that corresponds to many years of serious and consistent work.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/280568_b8d8387f94c8bb58_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280568
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/280568/130
Chartmaster
5月前
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.
CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz and placing the request within the formal institutional coordination channel, with an update expected as the internal process progresses. For CBIH, this step strengthens a strategic opportunity: to elevate public and institutional dialogue with a medical focus, advance evidence-based education, and promote serious standards for the responsible development of cannabinoid-derived therapies.
In parallel, CBIH is executing a multi-sector offensive to turn conversation into action through formal communications, calls, and direct coordination with pharmaceutical companies, healthcare organizations, institutional teams, and legislative offices, with a clear goal: moving from "interest" to technical working sessions and from "intention" to verifiable work plans.
On the financial front, the market is entering a phase of progressive normalization: as the federal framework evolves, more institutions and compliance teams are reassessing and building capabilities to serve the ecosystem under more structured risk and control models. In parallel, legislative initiatives such as the SAFER Banking Act continue to point toward greater clarity for financial services in the sector, reinforcing momentum toward broader integration.
"This is not about headlines; it is about evidence that withstands clinical and institutional review," said Rosangel Andrades, MD, CBIH R&D Director. "Our focus is to execute verifiable science: formulation, safety, delivery methods, and measurable outcomes, supported by compliance and real collaboration."
On the funding side, CBIH reported that it is giving full priority to its grants agenda through a pipeline-and-execution approach: identifying calls, aligning eligibility, structuring competitive proposals, and activating institutional partners. This momentum aligns with a tangible trend: meaningful funding is already being allocated to research and education related to medical cannabis and cannabinoids. For example, the California Department of Cannabis Control awarded nearly $30 million in competitive grants to nine academic institutions for 22 projects, marking the third round of this program and bringing the total to nearly $80 million since 2020.
"CBIH is in execution mode: institutions, grants, and evidence," said Jennifer Salguero, Biologist, PhD in Science, Chief Patent Officer, CBIH in Science, University of São Paulo, Brazil. "Our goal is to raise the standard and turn the therapeutic potential of cannabinoids into strong, responsible research that is useful for patients, physicians, and institutions."
CBIH reiterated that its platform integrates investigational formulations, a standardization-oriented vision, and a strategic approach focused on strengthening alliances with institutions and healthcare stakeholders that prioritize rigor, compliance, and outcomes, with a summary of its completed patent portfolio included in the table attached hereto.
Therapeutic Area Percentage (%) Number Disease/ Medical condition Patent Application Summary
Neurology / Psychiatry 40.91 9 Depression Advanced cannabinoid therapeutic composition targeting the microbiota-gut-brain axis for comprehensive depression management.
Anxiety Comprehensive cannabinoid compositions and methods for managing anxiety disorders.
Multiple Sclerosis Advanced cannabinoid formulation for targeted management of multiple sclerosis.
PTSD Therapeutic method utilizing cannabinoids and natural compounds for post-traumatic stress disorder (PTSD).
Dementia/ Alzheimer Nanoemulsion-based intranasal therapeutic formulation for treating Alzheimer's disease using neuroactive natural compounds.
Shingles Integrative treatment for shingles based on cannabinoid compounds (neuropathic component).
Acute Pain Acute pain management using cannabis-derived compounds.
CBDNopioid Use of Cannabinoids for Reducing Opioid Dependence
Autism In progress
Oncology 13.64 3 Pancreatic Cancer Method of treatment for pancreatic cancer.
Breast Cancer Cannabinoid-based nanoplatform composition and methods for treating breast cancer by inhibiting VEGF.
Sarcoma de Ewing Nanoemulsion-based therapeutic composition of cannabinoids and natural compounds for the treatment of Ewing sarcoma.
Endocrinology / Metabolic Diseases 13.64 3 Diabetes Oral liquid oil-in-water nanoemulsion comprising phytocannabinoids and bioactive natural compounds for metabolic regulation and management of type 2 diabetes mellitus.
Menopause Cannabinoid-based nanoplatform composition and methods for treating menopause symptoms.
Infertility +35 Optimized nanoemulsion delivery of antioxidants, cannabinoids, and nutraceuticals for age-related female fertility decline.
Rheumatology / Musculoskeletal 9.09 2 Osteoarthritis Cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis.
Collagen deficiency Nanoemulsion cannabinoid gummies promote collagen production and reduce symptoms related to collagen deficiency.
Gastroenterology / Microbiome Medicine 4.55 1 Dysbiosis Edible composition for the prevention and treatment of dysbiosis and gut-related disorders.
Ophthalmology 4.55 1 Glaucoma Sustained-release ophthalmic composition for targeted treatment of glaucoma and optic nerve degeneration.
Dentistry / Oral Medicine 4.55 1 Oral Care Cannabinoid formulations and methods for oral care and health management.
Infections 4.55 1 Respiratory Viral Infections Cannabinoid Composition and Method for Treating Symptoms of Respiratory Viral Infections
Gynecology / Sexual Medicine 4.55 1 Sexual dysfunction-related issues Polymer-based cannabinoid gel composition and methods for intimate lubrication.
Total 100.00 22
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/279973_d3d96b424477cb82_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279973
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/279973/130
TheBurn
5月前
Cannabis Bioscience International Holdings Inc @CBIHIR
CBIH Launches Federal & Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas – January 6, 2026 – Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process.
On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III as expeditiously as permitted by law, while expanding pathways for medical marijuana and cannabidiol research. CBIH views this moment as an urgent implementation window—where science, patents, and credible education must move in parallel to ensure the policy direction translates into measurable outcomes.
Since this federal directive, CBIH has intensified outreach—through calls, emails, and formal correspondence—to pharmaceutical companies, members of Congress, U.S. Senators, and federal stakeholders whose agencies and committees influence research pathways and execution, including (among others) the U.S. Department of Justice, the Drug Enforcement Administration (DEA), and the Centers for Medicare & Medicaid Services (CMS). CBIH’s objective is to build working relationships that can help align clinical research standards, clarify available research mechanisms, and accelerate compliant programs supported by defensible intellectual property.
“Policy momentum alone is not enough,” said Rosangel Andrades, MD, CBIH R&D Director. “The Schedule III transition is a once-in-a-generation inflection point—yet the real impact will be determined by execution: standards, research infrastructure, and the ability to translate science into compliant clinical pathways. We believe CBIH can help accelerate that execution.”
CBIH’s platform includes investigational medical formulations targeting high-need conditions, a robust IP strategy, and a scalable education model designed to support medical and regulatory stakeholders. CBIH reports it has 10 patent applications already filed with the USPTO and 12 additional filings finalized and ready for submission, aimed at pharmaceutical-grade formulation standards and structured clinical development.
As part of this initiative, CBIH is actively mapping which federal and private funding mechanisms may become available for research, identifying committees and working groups shaping protocol and implementation, and offering its patent-driven assets and education infrastructure as practical tools to support responsible, science-first progress.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at http://OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: http://cbih.net
X: http://x.com/CBIHIR/
Instagram: http://instagram.com/CBIHSTOCK
#CBIH #OTCMarkets #MedicalCannabis #CannabinoidResearch #CBIHStock
Last edited
5:37 PM · Jan 6, 2026 · 49 Views
Chartmaster
5月前
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process.
On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III as expeditiously as permitted by law, while expanding pathways for medical marijuana and cannabidiol research. CBIH views this moment as an urgent implementation window-where science, patents, and credible education must move in parallel to ensure the policy direction translates into measurable outcomes.
Since this federal directive, CBIH has intensified outreach-through calls, emails, and formal correspondence-to pharmaceutical companies, members of Congress, U.S. Senators, and federal stakeholders whose agencies and committees influence research pathways and execution, including (among others) the U.S. Department of Justice, the Drug Enforcement Administration (DEA), and the Centers for Medicare & Medicaid Services (CMS). CBIH's objective is to build working relationships that can help align clinical research standards, clarify available research mechanisms, and accelerate compliant programs supported by defensible intellectual property.
"Policy momentum alone is not enough," said Rosangel Andrades, MD, CBIH R&D Director. "The Schedule III transition is a once-in-a-generation inflection point-yet the real impact will be determined by execution: standards, research infrastructure, and the ability to translate science into compliant clinical pathways. We believe CBIH can help accelerate that execution."
CBIH's platform includes investigational medical formulations targeting high-need conditions, a robust IP strategy, and a scalable education model designed to support medical and regulatory stakeholders. CBIH reports it has 10 patent applications already filed with the USPTO and 12 additional filings finalized and ready for submission, aimed at pharmaceutical-grade formulation standards and structured clinical development.
As part of this initiative, CBIH is actively mapping which federal and private funding mechanisms may become available for research, identifying committees and working groups shaping protocol and implementation, and offering its patent-driven assets and education infrastructure as practical tools to support responsible, science-first progress.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.netX: www.x.com/CBIHIR/Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/279386_27668f2564ae9b02_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279386
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/279386/130
Chartmaster
6月前
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States.
According to U.S. public health data, more than 700,000 people have died from opioid-involved overdoses since the early 2000s. Despite recent progress, the crisis remains severe: in 2024 alone, an estimated 54,743 Americans died from opioid-related overdoses, even as overall overdose deaths declined compared to prior years.
"Opioid addiction is not simply a matter of 'willpower' or a single drug--it is a complex, chronic psychiatric and medical condition," said Rosangel Andrades, MD, CBIH R&D Director. "As a health-focused company, we believe it is both a public health priority and a moral obligation to contribute serious, science-based solutions for a community that has often been stigmatized and neglected."
From a psychiatric standpoint, opioid use disorder significantly increases the risk of other mental and physical comorbidities. Physiologically, opioids bind to receptors in critical regions of the brainstem and can trigger respiratory depression, frequently leading to fatal outcomes. These mechanisms make opioids a "silent killer" whose risk profile varies by molecule but is consistently severe.
Building on this understanding, CBIH's patent initiative focuses on reward circuits in the brain and the endocannabinoid system, which is widely expressed in those pathways. The goal of the investigational approach is to support the brain during recovery, particularly in the vulnerable post-detox phase, by exploring ways to:
Modulate intercellular communication in key neural circuits.
Alleviate withdrawal-related symptoms.
Reduce vulnerability to relapse by promoting greater neurobiological balance.
Recovery is one of the most fragile stages in the rehabilitation process: many individuals who successfully complete detoxification ultimately relapse during this period. CBIH's research program is therefore centered on this critical window, seeking to complement existing treatments with cannabinoid-based strategies that may help an "addicted brain" gradually regain stability and resilience. "This formulation will be presented to Mr. Robert F. Kennedy Jr., Secretary of Health and Human Services, to explore opportunities for potential collaboration in research and to evaluate possible next steps," Mr. John Jones, CBIH Treasurer, added.
"This patent effort is about more than commercial opportunity," Dr. Andrades added. "It is a social and medical commitment: to treat people with opioid use disorder with the same urgency and dignity that we devote to conditions like cancer, diabetes, or heart disease. Stigma should never stand in the way of science, compassion, or care."
Following President Donald J. Trump's December 18, 2025 Executive Order directing the Attorney General and relevant federal agencies to expedite the completion of the ongoing federal process to reclassify cannabis from Schedule I to Schedule III, and to expand medical marijuana and cannabidiol research, CBIH, more than ever, continues to invest in science-first medical cannabis innovation through its formulations and patent portfolio, and views this policy direction as an opportunity to expand dialogue with pharmaceutical partners, regulators, and other industry rulemakers to advance compliant clinical research and responsible product development.
As we close 2025, CBIH extends its sincere gratitude to patients, researchers, partners, and shareholders for their continued support, and wishes everyone a healthy, peaceful, and prosperous New Year.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.netX: www.x.com/CBIHIR/Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/279086_0c0e854844f37a75_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279086
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/279086/130
Chartmaster
6月前
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate.
After eighteen years of navigating scientific challenges, market volatility, stigma, and regulatory uncertainty, CBIH stated that this turning point carries profound meaning for companies that have remained committed to rigorous medical science.
CBIH Treasurer and Director, Mr. John Jones, noted that the company has experienced "the good, the difficult, and the indifferent," yet has sustained its founding scientific vision despite intense headwinds. He highlighted that the rescheduling to Schedule III opens the door to conversations with pharmaceutical companies, strengthens dialogue with government officials regarding CBIH university medical cannabis programs, and accelerates the path for medical formulations and submitted patents currently under review.
"The stigma surrounding cannabis has distorted reality for almost two decades," Mr. Jones said. "This moment represents the beginning of a new era. The difficult years are now in the rear-view mirror, and we are grateful for President Trump's leadership in supporting a policy shift that aligns science, public health, and economic opportunity. It is a meaningful year-end milestone and a compelling start to 2026."
For CBIH, the potential transition from Schedule I to Schedule III transforms the company's long-term vision from a hypothetical future into a tangible present. The company emphasized that its future is no longer speculative; it is unfolding now.
Our responsibility is to connect the dots in this extraordinary present. With greater regulatory clarity on the horizon, CBIH is positioned to enter a phase of accelerated growth supported by scientific discipline, strategic intellectual property development, and an expanding ecosystem of educational and medical initiatives.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/278735_cb5abb78943f0b9f_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278735
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/278735/130
Chartmaster
6月前
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III.
CBIH believes that, if the process moves forward, it could represent one of the most consequential federal shifts since the 1970s. CBIH views Schedule III as a bridge toward improved research access, clearer pharmaceutical development pathways, and more responsible medical adoption.
In that historical context, CBIH emphasizes that its advantage has not been speculation, but sustained preparation for an increasingly demanding regulatory environment. The Company has focused its strategy on pillars that often distinguish a "consumer" industry from a "healthcare" industry: intellectual property, standardizable formulations, scalable scientific platforms, and educational programs designed to elevate medical and regulatory standards. With this approach, CBIH states that it has positioned itself to actively contribute to the advancement of cannabis as evidence-based medicine.
"We have prepared for this moment with a long-term vision," said Rosangel Andrades, MD, Research Director at CBIH. "If rescheduling to Schedule III becomes a reality, our next step is to further strengthen our scientific standards and advance toward a 'Magnet-ready' level of institutional excellence in the science of cannabinoids as medicine, with processes, clinical evidence, and operational quality aligned with the highest best practices in the healthcare sector."
"CBIH believes that Schedule III can support a more investable environment that is more attractive to institutional capital by enabling more standardized research conditions, clearer medical positioning, and improved operating realities for companies that comply with applicable regulatory frameworks, quality standards, and responsible corporate governance practices," said John Jones, Board Director of CBIH.
From an economic standpoint, the scale is already undeniable: Whitney Economics projected that legal cannabis sales in the United States would exceed $31.4 billion in 2024, representing an increase of approximately $2.6 billion versus 2023 (about 9.14% year over year). In parallel, industry employment estimates place the legal market at 425,002 jobs supported across the United States. Looking ahead, sector analyses have projected that legal retail cannabis sales in the United States could exceed $53.5 billion by 2027, reflecting the magnitude of the potential growth if regulatory expansion continues.
Looking to 2026, CBIH expects to accelerate initiatives that strengthen its scientific and educational model, expand strategic partnerships, and advance developments focused on standardization, applied research, and responsible medical adoption, with the goal of converting regulatory clarity into measurable progress for patients, healthcare professionals, and funding institutions.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.netX: www.x.com/CBIHIR/Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/278005_5ef3c9c3d4d92ae6_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278005
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/278005/130
Chartmaster
8月前
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners.
As age is a key determinant of reproductive outcomes—and first births are occurring later—the need for effective, evidence-based solutions is increasingly clear. In the United States, since 1990, birth rates have climbed 71% for women 35–39 and 127% for women 40–44. These trends, we believe, underscore the importance of approaches that protect ovarian reserve, enhance oocyte maturation, and support implantation.
"Despite these numbers, women's conditions continue to receive too little attention—underfunded and understudied relative to their burden," said Rosangel Andrades, MD, R&D Director. "Recent NIH budgets dedicate only about 8–9% to women's health. At CBIH, we believe we should help change that. We are committed to placing women at the center of innovation—listening with empathy, investing with intention, and advancing solutions that we expect will meet real needs from reproductive health to healthy aging, including unresearched conditions such as endometriosis and fibromyalgia," she added.
CBIH's invention centers cannabinoids as the primary therapeutic drivers, integrating them with select antioxidants, polyphenols, fatty acids, and complementary bioactives to target the key mechanisms of age-related reproductive decline. Cannabinoids are positioned to modulate mitochondrial function, redox balance, and cytokine signaling within ovarian and endometrial tissues, with the goal of improving oocyte competence and endometrial receptivity. The nanoemulsion delivery system is engineered to enhance the solubility, colloidal stability, and bioavailability of these lipophilic cannabinoids, thereby we expect to increase tissue exposure at reproductive targets. By coupling cannabinoid-focused pharmacology with supportive cofactors that address oxidative stress and low-grade inflammation, the formulation is designed—and we believe should be well-suited—to optimize the follicular microenvironment, bolster implantation readiness, and operate as an adjunct to assisted reproductive technologies without displacing the current standard of care.
"As CBIH scales its patent estate, we believe we are creating a clear path to attractive returns: a defensible, IP-backed nanoemulsion platform that should meet pharma's bar for exclusivity, manufacturability, and line-extension potential. This positioning would make the asset attractive for near-term out-licensing or co-development with potential milestone and royalty upside—and, as clinical and regulatory milestones are achieved, we expect it could become a credible acquisition outcome", states John Jones, CBIH Treasurer and Director.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/270001_304fa62c64b10b20_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270001
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/270001/130
https://www.otcmarkets.com/stock/CBIH/news/CBIH-Announces-Women-First-Fertility-Innovation-Built-on-Nanoemulsion-Delivery?id=495736
Chartmaster
8月前
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder value.
A decorated U.S. Marine Corps veteran and seasoned financial strategist, Mr. Trivedi brings over two decades of leadership experience spanning Fortune 500 corporations, entrepreneurial ventures, and emerging growth sectors. His expertise in capital raising, financial structuring, and corporate growth strategy will directly support CBIH's plans for expansion and innovation in the rapidly evolving biomedical cannabis industry.
Mr. Trivedi currently serves as Chief Financial Officer of Newable Power LLC, where he has successfully led capital development and financial planning for high-growth energy ventures. His prior leadership roles at Hewlett-Packard, GE, Air Liquide, Siemens, and FMC underscore a proven track record in building scalable business models and forging strategic partnerships across global industries.
As a member of the Board, Mr. Trivedi will lead CBIH's efforts in capital strategy, investor engagement, and long-term corporate development, reinforcing the Company's ability to attract institutional partners and advance its position in medical cannabis research.
"The appointment of Mr. Andy Trivedi to our Board comes at a defining moment for CBIH," said Mr. John Jones, Treasurer and Director. "While the industry has been challenging to navigate, constraints on the resources required to scale—not capability—have delayed our product rollouts. Andy's proven guidance in complex financial markets will serve as a catalyst, helping us open new avenues of support, advance strategic collaborations, connect with additional financial partners, and secure the backing we need now to bring our products to market, all while maintaining our standards of safety, efficacy, and innovation."
Mr. Trivedi earned his MBA in Strategic Management from the UHV and a BBA in Risk Management and Finance from the UHD. In addition to his corporate achievements, he has been an active supporter of veteran initiatives and small business development programs, underscoring his commitment to community and sustainable growth.
By integrating proven financial leadership into its governance structure, CBIH is positioning itself to seize upcoming opportunities in the medical cannabis sector and deliver sustainable value for shareholders.
About Cannabis Bioscience International Holdings, Inc.
CBIH focuses on driving the science, safety, and effectiveness of cannabinoid-driven treatments. Through educational initiatives, clinical studies, and breakthrough product development, the company intends to improve patient care, inspire investor confidence, and set a higher bar for medical cannabis.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/269146_9e4b10ba341e2bfc_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269146
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/269146/130
https://www.otcmarkets.com/stock/CBIH/news/Cannabis-Bioscience-International-Holdings-Inc-Appoints-Veteran-Financier-Andy-Trivedi-to-Its-Board-of-Directors-Strengt?id=494796
Chartmaster
9月前
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among others, and will directly benefit more than one million Texans, including 300,000 veterans. The law also updates permissible cannabinoid concentrations, signaling a decisive step toward integrating cannabis-based therapies into clinical practice.
The Statewide Educational Seminar Series will take place in key cities: UTHealth Houston — November 15, 2025; Austin, TX — December 6, 2025; Dallas, TX — January 17, 2026; El Paso, TX — February 21, 2026. Sessions will address patient registration, prescriber responsibilities, regulatory and liability considerations, reimbursement pathways, and the latest evidence in cannabinoid science.
Figure 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10188/268301_flyer_seminario_tcup_1.jpg
CBIH is also entering a stage of accelerated growth driven by key factors such as cannabis tax reductions in California, the expansion of legislation in Texas, regulatory updates in Delaware, and progress toward banking reform. These developments directly strengthen the company's revenue outlook and reinforce its market position. Jennifer Salguero Ph.D. in Sciences noted that the cannabis industry is moving toward unprecedented financial stability, creating a unique opportunity for CBIH to increase its revenue streams, expand its educational/research programs, and deliver sustained value to CBIH revenue-generating centers.
"This is a transformative milestone for medical cannabis in Texas," said Rosangel Andrades, M.D., CBIH Director of R&D. "Participants will not only stay informed-they will help shape patient care, professional practice, and the scientific agenda ahead."
Cannabis Bioscience International Holdings is a global leader in cannabis research and education, with a track record of government-authorized training partnership in Puerto Rico and six years of accredited programs across six universities in Colombia. CBIH's library includes 150+ instructional videos and 250+ eBooks and audiobooks in seven languages, equipping professionals to integrate cannabis therapies safely and scientifically.
For the agenda, speaker bios and abstracts — Julian González, M.D. (Clinical Medicine), and Brian Cuban, Esq. (Legal Perspectives / Law & Professional Well-Being) — as well as ongoing updates, please visit the event webpage: www.vitabiotechresearch.com. This is a watershed moment for healthcare in Texas-one that reflects a shared commitment to science, safety, and patient dignity, and that sets the stage for evidence-based practice, responsible policy, and improved patient outcomes in the years ahead.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/268301_6d3124e7f49e6ab0_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268301
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/268301/130
https://www.otcmarkets.com/stock/CBIH/news/CBIH-Ignites-Texas-Statewide-TCUP-Seminar-Marks-a-New-Era-for-Medical-Cannabis-With-Evidence-Safety-and-Patient-Dignity-?id=493954
Chartmaster
1年前
Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products
HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry.
Stephen Gould, a company with a remarkable presence in over 40 locations across six countries, brings an extraordinary legacy of expertise to this partnership. Known for its tailored, locally-oriented solutions, Stephen Gould’s robust global network and prestigious client portfolio—including Walmart, The Children’s Place, GoPro, and Verizon—make it the perfect ally in CBIH’s mission to transform lives through science-backed medical products.
“This partnership is a moment of immense pride for CBIH, as it enables us to fast-track the delivery of our innovative formulations to market,” says Rosangel Andrades, CBIH R&D Director.
With over 80 years of experience and a well-deserved reputation as one of the largest distributors in the United States, Stephen Gould embodies the operational excellence and industry reach that aligns perfectly with our vision. Their unparalleled capabilities in logistics, production management, product marketing, fulfillment, design, and inventory control provide the ideal foundation for this collaboration.
Under the agreement, CBIH will contribute its proprietary medical formulations, while Stephen Gould will take the lead in manufacturing and distribution operations. This collaboration is a testament to our dedication to bringing transformative medical products to patients swiftly and efficiently. We are ecstatic to announce that the first wave of products is set to launch in the first quarter of 2025, a milestone that we could not have achieved without the expertise and commitment of our partners at Stephen Gould.
This partnership reaffirms CBIH’s unwavering commitment to delivering quality, science-driven medical solutions. With Stephen Gould’s support, we are confident in our ability to expand our market reach and operational efficiency.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://www.globenewswire.com/newsroom/ti?nf=OTMyNjk1MyM2Njc5OTI1IzIyOTIzMDQ=
https://ml.globenewswire.com/media/ODJkM2IxZjctMWE2OS00MzVhLTg4YjktMGY4ZTQwMjdkNDhhLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2025 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3092800
Chartmaster
2年前
A Letter from the Desk of CBIH
HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings
Dear Community,
On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility.
CBIH remains committed to actively participating in these hearings, which represent a crucial moment for the future of cannabis in medical and scientific advancement. The discussions include at least 20 groups, 10 in opposition and 10 in support, highlighting the intense debate surrounding this critical issue.
The proposed reclassification of cannabis from Schedule I to Schedule III could usher in transformative changes. It would pave the way for advanced research, facilitate the development of safe and effective treatments for chronic and hard-to-treat conditions, and significantly improve the quality of life for patients. Beyond medicine, this change could drive economic growth by creating jobs, attracting investment, supporting small businesses, and providing a boost to the national economy.
This is a once-in-a-lifetime opportunity, and we must recognize its magnitude. If the reclassification effort does not succeed, we may not have another chance to revisit this discussion for another 8–10 years. That is why I am calling on all stakeholders, patients willing to share their stories, especially those with multiple sclerosis and epilepsy who have found relief through medical cannabis, medical experts who can validate cannabis’s therapeutic benefits, and legal professionals equipped to navigate this complex process, to join us in this crucial mission and participate as one of CBIH’s expert witnesses in the next DEA Hearing.
Time is of the essence. We have just a narrow window to act, with a deadline of Wednesday, December 11, at 5:00 PM CT, to assemble our team of contributors. Over the next three months, we will require robust legal and scientific support to counter significant opposition, including government testimony and representation from major law firms. The expertise and participation of people who understand the necessity of this reclassification can make a meaningful difference in ensuring that we advocate effectively for this vital cause.
If you are a scientist, medical expert, patient, or legal professional and wish to contribute to this effort, please contact us via email at ir@cbih.net.
The reclassification of cannabis is more than a policy change, it is an opportunity to revolutionize quality of life, stimulate economic growth, and open doors to innovation. Please keep in mind that if Americans want cannabis to be reclassified from Schedule I to III, we are going to have to fight for it.
Thank you for your support.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://www.globenewswire.com/newsroom/ti?nf=OTMxNTg3MiM2NjI3ODQ1IzIyOTIzMDQ=
https://ml.globenewswire.com/media/MjMzODRjZjMtMmMxNS00MGY1LWIzY2UtNjk4NjFkNDdlZmVlLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3069453
Chartmaster
2年前
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical cannabinoid products.
These initiatives are driven by CBIH's commitment to enhancing quality of life for individuals facing chronic, degenerative, and life-threatening illnesses. Moreover, the company aims to lead the future of medicine by developing innovative solutions such as mRNA vaccines for cancer and other prevalent diseases that are transforming modern medicine.
“Our mission goes beyond innovation: we aim to revolutionize the pharmaceutical industry with personalized, accessible treatments designed to significantly improve patients' quality of life. By focusing on molecular biology, nuclear medicine, genetics, and advanced technologies such as nanotechnology, picotechnology and femtotechnology, we are creating highly targeted cannabinoid-based drugs that meet the unique needs of a broader spectrum of patients,” says Rosangel Andrades, CBIH R&D Director.
As we near our product launch and continue to submit medical patents (13) to the USPTO, CBIH remains focused on strengthening our team to advance production and drive innovative research. Our goal is to position the company as an attractive partner for larger pharmaceutical firms, fostering opportunities for strategic alliances. We aim to lead the way in transformative therapeutic solutions using scientifically validated medical cannabinoids, capitalizing on the coming opportunities arising from the possible reclassification of cannabis from Schedule I to Schedule III.
Under the leadership of Dr. Andrades, our R&D division has expanded significantly, enhancing our expertise and specialized teams to drive CBIH's accelerated growth. This enhanced talent pool empowers us to establish a sustainable product sales pipeline while maintaining the highest scientific and clinical standards.
Our R&D team is proud to include Dr. Stephanie Hartmann, M.D., and Dr. Yesiree Baptista, M.D., both distinguished medical practitioners and Principal Investigators in Cannabinoid Therapies. We are also supported by Dr. Jennifer Salgueiro, Ph.D. in Microbiology, and Dr. Nancy Duarte, Ph.D. in Biology and Immunology, whose molecular science expertise is instrumental in identifying new therapeutic targets within cannabinoid research. Additionally, our formulation department is reinforced by Dr. Laura Reina, Formulation Pharmacist, Dr. Ana María Maldonado, Ph.D. in Pharmacy, and Dr. Angélica Clavijo, Master in Process Design and Management, MBA, who bring invaluable expertise to our team.
"With a team of highly qualified professionals, the company is committed to addressing critical challenges such as mental health disorders. Recognizing that these conditions can profoundly impact individuals across all demographics and acknowledging the limited efficacy and accessibility of current treatment options, we strive to pioneer innovative, science-based solutions and to expand the therapeutic landscape to those in need,” says Brian Cuban, CBIH Advisory Director.
By fortifying its team with distinguished professionals, CBIH is strategically positioned to lead in the medical cannabis retail market and reinforce its role as a pioneer in scientific and medical research. With a deep commitment to advancing cannabinoid chemistry and innovative health solutions, CBIH aims to become a dominant force in the medical cannabis industry and the premier choice in national retailers.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://www.globenewswire.com/newsroom/ti?nf=OTI3NTE5MyM2NTg2OTI3IzIyOTIzMDQ=
https://ml.globenewswire.com/media/ZjYzNTdkZjctZjY2NC00ZTQ4LTliNmUtOGJiYTEzYTFlODcwLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3050173
Chartmaster
2年前
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - November 4, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to announce the appointment of Mr. Charles Tamburello as a new member of the board of directors. His extensive experience in the public markets, which spans nearly three decades, will play a crucial role in driving the company's mergers and acquisitions (M&A) strategy forward.
Mr. Tamburello has been instrumental in the success of hundreds of public and private companies since 1995, leveraging his deep industry knowledge and valuable connections to facilitate growth and expansion. His track record of orchestrating successful M&A transactions aligns perfectly with CBIH's strategic goals as we look to enhance our capabilities and reach. He is the owner operator of Global Discovery Group, a dynamic platform designed to facilitate engagement between public companies and the investment community, which offers a highly effective and time-efficient way for companies to showcase their latest developments, new products, services, and significant announcements.
"Recognizing the challenges ahead as we strive to reach our ambitious benchmarks, we are committed to bringing on top-tier talent and strategic guidance. Mr. Tamburello exemplifies this commitment," said John Jones, CBIH Treasurer and Director. "His extensive experience in capital acquisition and expertise in navigating complex industries will provide our shareholders with confidence that we are positioned for sustainable growth and value creation."
Charles Tamburello expressed his enthusiasm about joining CBIH, stating, "I'm excited to be a part of the vision of Cannabis Bioscience International and the journey of helping everyday people throughout the world, conquer debilitating ailments and improve their lives."
Mr. Tamburello's appointment to the CBIH board significantly strengthens the company's potential for successful mergers and acquisitions (M&A). His extensive background in executing M&A transactions across diverse sectors equips CBIH with the strategic insights and negotiation skills necessary to identify high-value acquisition targets and maximize deal success. Tamburello's deep industry connections and leadership of The Emerging Growth Conference provide CBIH with enhanced access to potential partners and acquisition opportunities, increasing the likelihood of securing advantageous deals that align with CBIH's growth objectives.
Furthermore, his expertise in capital raising allows CBIH to pursue acquisitions more aggressively, ensuring the company has the necessary resources to act swiftly on opportunities and expand its portfolio. This combination of M&A experience, industry influence, and capital acquisition skills provides CBIH with a competitive edge, enabling the company to grow strategically through targeted acquisitions that bolster its market position and drive long-term shareholder value.
This powerful combination of skills and connections positions CBIH to seize high-value opportunities and strategically expand our portfolio, strengthening our market position and delivering sustained value for shareholders. With Mr. Tamburello's leadership, we are more confident than ever in our path to becoming an industry leader and achieving long-term, transformative growth.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/228741_2ab2feab447cd92f_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228741
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/228741/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3034183
Chartmaster
2年前
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
GLOBENEWSWIRE 6:00 AM ET 7/15/2024
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings(CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range.
Preparations are underway for the production and distribution of our products, and continue to foster revenue expansion, which could only be achieved through the practical application of the skills and experiences gained over the past 15 years. Therefore, we are now navigating the licensing phase for our manufacturing units. This involves securing permissions for the production, manufacture and provision of cannabinoid-based items.
Moreover, our firm is deeply invested in maintaining the highest standards of regulatory compliance. In pursuit of this goal, the company has diligently applied for licenses required under Texas state laws, including the Retail Hemp Registration (#8305) from the Texas Department of State Health Services (DSHS), alongside the Initial Food Manufacturer License (#1037264) and Initial Food & Drug Owner application (#1037264).
Amidst ongoing project development and meticulous refinement of patent applications for our formulations and preparing for the development of clinical data trials aimed at validating our products effectiveness, CBIH remains focused on introducing novel revenue-generating avenues through dietary supplements and nutraceuticals. Through a potential strategic alliance with a distinguished national product manufacturer, CBIH looks forward to launching its cannabis-based products to the market for the first time.
"The cannabis industry has encountered major hurdles due to unclear regulations, leading to difficulties for several companies in this sector. Hence, we feel immense pride in our capacity to have been able to withstand the test of time, showcasing our resilience as CBIH seeks to gain a considerable segment of the market and ultimately achieve our pioneering goals. These initiatives collectively function as preparatory measures in light of the prospect of cannabis being reclassified as medicine, propelled by CBIH's competitive drive to spearhead the utilization of this groundbreaking shift," remarks John Jones, CBIH Treasurer and Board Director.
“This has been a journey in the making, and with the successful application of our licenses, we remain committed to strictly adhering to both federal and state regulations and the essence of the law. Our focus is on developing our products as vitamins or nutraceuticals, acknowledging the undeniable therapeutic advantages of cannabis as a form of medicine. At the core of our mission, if our products can offer healing or significantly improve the quality of life for patients, the legality surrounding medical claims becomes secondary. What matters most is harnessing the potential of cannabis compounds to aid those that traditional medicine has forgotten. It is about non-traditional medicine in a traditional world,” says Rosangel Andrades, Research and Development Director.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
Image: https://www.globenewswire.com/newsroom/ti?nf=OTE3NzYwMyM2MzY2MDgzIzIyOTIzMDQ=
Image: https://ml.globenewswire.com/media/NzBhZjhkZGMtNzJjZi00MjM4LWE2MTItZTExZDVlYjNlZGQzLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Image: Primary Logo
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.(CBIH)
Chartmaster
2年前
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
Newsfile Corp.
Newsfile Corp
A letter from our desk
Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications.
From our desks - Rosangel Andrades and Jennifer Salguero.
In the realm of medicine, patent requirements diverge from other forms of intellectual property, as clinical trials or studies are required to substantiate the attributes assigned to a compound.
While CBIH excels in bringing scientific rigor to the table, we acknowledge the imperative need for self-conducted studies. Our strategy unfolds in two primary directions. Initially, to amass comprehensive clinical evidence for our therapeutic interventions. Subsequently, to seize the opportunity presented by the impending declassification of cannabis, making clinical trials a focal point for numerous institutions and pharmaceutical entities. As we brace for the unfolding opportunities post-declassification, CBIH is strategically positioned to lead, thanks to our unique expertise as one of the limited clinical research units specializing exclusively in cannabis, thus, allowing us to generate additional revenues. This distinction would set us apart, given the scarcity of CRUs with comparable experience and understanding of cannabis clinical trials.
Moreover, we advocate for the utilization of provisional patents, which offer a 12-month grace period for conducting the requisite trials. These trials can encompass a variety of methodologies, including in vivo and in vitro preclinical studies, animal model testing, or leveraging single-cell studies.
For more information on single cells studies, please visit: drive.google.com/file/d/1yuCVocWQqq1B6EqN1G5jlzy8g8LGuQSC/view?usp=sharing
Furthermore, we intend to file all our patents with the United States Patent and Trademark Office (USPTO), targeting the lucrative U.S. market. This strategic filing not only strengthens our presence in the industry but also paves the way for collaborations with pharmaceutical companies exploring the potential of cannabinoid compounds. Our patent assets are poised to become a significant source of revenue. It's noteworthy that a 2019 Statista report indicated AbbVie's dominance with 59 cannabis patents, compared to Pfizer's 25. Given Pfizer's track record of striving for industry leadership, it's conceivable that they would be motivated to acquire more cannabis patents to assert their dominance in this emerging field.
In consequence, our objective is to tackle diseases that have been consistently overlooked and face a scarcity of effective treatments, such as menopause syndrome that could affect quite literally any woman in their lifespan, and Ewing cancer which is a severe and devastating condition that affects bones and soft tissue in adolescents. Our team is committed to addressing those neglected by conventional medical research.
From my desk - John Jones.
Evaluating our company's worth was a crucial move for our company, especially in light of potential merger and acquisition discussions. Identifying the right partner for such a significant endeavor remains our priority. Our goal transcends mere transactions; we seek a mutually beneficial partnership that thrives over time, making the selection of the perfect collaborator our greatest challenge. Moreover, achieving a valuation of $2 billion is no small feat, it is a testament to the hard work, dedication, and innovative spirit of our team.
Our agreement with VITA Biotech Research has facilitated the receipt of the second installment of $50,000 for CBIH, catalyzing advancements in the marketing and development of our nutraceuticals.
Additionally, this partnership has facilitated our ability to register trademarks for our product names, which will be sold as dietary supplements, nutraceuticals, or vitamins, adhering to local regulations. This strategic move holds significant value for our company, as certain vitamins, such as our Cancer VITA or Precancer VITA, could exert a remarkable influence if they gain distribution through retailers like Walmart or Walgreens. This highlights the critical importance of differentiating our products from those of competitors by trademarks.
Initiatives like this infuse the company with a fresh and profound value. Conversely, a firm that disregards patenting, omits trademarking, dismisses valuation, and fails to form elite distributor partnerships essentially loses its worth. Therefore, every step taken, every seed planted, dramatically elevates the company's value.
As CBIH continues to expand, we remain committed to investing time, effort, and thoughtful consideration into our endeavors that ultimately transform into revenues, predominantly because we cannot be a company that can't see the forest from the tree. Instead, we are gaining sustainable competitive advantage in the industry.
Each step we undertake lays the groundwork for future successes, mirroring the trajectory of companies that have transformed from modest beginnings to industry leaders. We are poised for a prosperous future, driven by various revenue generation centers, strategic partnerships, and continued growth.
FORWARD-LOOKING STATEMENTSThis press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://images.newsfilecorp.com/files/10188/215666_012882b504f37b28_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215666
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/215666/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2910920
Chartmaster
2年前
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
HOUSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration.
Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic cancers. These conditions, affecting millions globally, present unique challenges due to their prevalence and the severity of their outcomes. Breast cancer, for instance, impacts approximately one in eight women in the United States over their lifetime, while pancreatic cancer is notorious for its late-stage diagnosis and grim prognosis, with a five-year survival rate below 10%.
Jennifer Salguero, PhD in Science with emphasis on Microbiology, highlights the urgency and strategic focus of our approach: "Given the stark statistics associated with these cancers, our team recognizes the critical need for aggressive yet targeted interventions. Our aim is to not only target the tumors but also safeguard surrounding tissues, leveraging the inherent antitumor properties of cannabinoids."
CBIH aims to accelerate our pace of innovation by submitting an additional 3 to 4 patents per month throughout the remainder of the year. Among our top priorities are patents related to the treatment of herpes zoster, knee osteoarthritis, and Alzheimer's disease, harnessing the antiviral, anti-inflammatory, and neuroprotective benefits of cannabinoids.
To support this goal, we are expanding and strengthening our research team, focusing on patent and formulation development. We are honored to welcome Sheila Tarqui, with a comprehensive background in biology, pharmaceutical chemistry, public health, and dermatic cosmetics, enriched by her education from Ricardo Palma University, María Auxiliadora University, San Juan Bautista Private University (Peru), and Francisco de Vitoria University (Madrid, España), makes her an invaluable addition. We expect Tarqui’s expertise will significantly contribute to advancing our innovation and maintaining our high standards of excellence.
Moreover, we are proactively trying to recruit medical specialists in oncology and cardiology to deepen our exploration of cannabis compounds' therapeutic applications. Despite substantial existing research, cardiovascular diseases persist as the world's leading cause of death, with limited understanding of cannabinoids' potential in this field. Identifying this as an emerging opportunity, we see the combination of cardiovascular medicine and cannabinoid research as a promising path for developing innovative treatments. Our recruitment efforts aim to fill this knowledge gap and unlock new possibilities for addressing prevalent and life-threatening conditions worldwide.
"These strategies contribute to securing and protecting our intellectual property which is paramount. By harnessing cutting-edge therapies, artificial intelligence, and advanced biotechnological techniques, we aim to safeguard and successfully market our groundbreaking medical advancements" says Rosangel Andrades, Research and Development Department Director.
We remain steadfast in our mission to leverage the full potential of cannabinoids to improve patient outcomes and contribute to global health initiatives. At CBIH, we are redefining medicine and treatment strategies.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://www.globenewswire.com/newsroom/ti?nf=OTE3MTQzNCM2MzQ4NzkyIzIyOTIzMDQ=
https://ml.globenewswire.com/media/NjJhZDk4NzYtYmVhMy00ODZhLTk5NTQtNGQ2OTIyOTRkYTA2LTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2905906
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Rainer
2週前
okwife
2月前
cudaguy
6月前
メールアドレスで登録
